Live Breaking News & Updates on Filgotinib

Stay updated with breaking news from Filgotinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SELECTION, SELECTIONLTE Show Safety of Filgotinib for Ulcerative Colitis

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups. ....

Stefan Schreiber , Kiel University , Galapagos Health Stefan Schreiber , Galapagos Health , Accessed September , Ulcerative Colitis ,

Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA ....

Nordrhein Westfalen , Region Flamande , United Kingdom , Northern Ireland , Great Britain , Van Gijsel , Marieke Vermeersch , Daniele Dambrosio , Xenofon Baraliakos , Elisa Chenailler , Sandra Cauwenberghs , European Union , Japanese Ministry Of Health , University Bochum , Exchange Commission , European Medicines Agency , Gilead Sciences Inc , Percentage Of Participants Achieving Spondyloarthritis International Society , Axspa Topline , Ankylosing Spondylitis Disease Activity Score , Internal Medicine , Ruhr University Bochum , Coordinating Investigator , Danieled Ambrosio , Therapeutic Area Head , European Summary ,

Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib ....

United Kingdom , Region Flamande , Northern Ireland , City Of , Great Britain , Daniele Dambrosio , Dennis Riedl , Ailsa Hart , Roberta Loveikyte , Kristina Harris , Pieter Jan Stiers , Katrien Van Beneden , Van Gijsel , Briang Feagan , Takayuki Matsumoto , Andreas Sturm , Christine Rudolph , Hannah Knight , Eva Santermans , Brian Feagan , Stefan Schreiber , Fatima Dawod , Tadakazu Hisamatsu , Karine Muller , Roger Rolph , Marieke Vermeersch ,

Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints ....

Region Flamande , United Kingdom , Northern Ireland , Great Britain , Daniele Dambrosio , Van Gijsel , Sandra Cauwenberghs , Marieke Vermeersch , Schwierige Zeiten , Elisa Chenailler , Gastroenterology Department Of The University Hospital Leuven , Group Biomedical Sciences , European Parliament , Gilead Sciences Inc , Exchange Commission , Japanese Ministry Of Health , European Union , University Of Leuven , Marketing Authorization Application , Patient Reported Outcome , Simple Endoscopic Score , Research Director , Gastroenterology Department , University Hospital Leuven , Therapeutic Area Head , Disease Activity Index ,

Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies

Gilead Sciences K.K.(Headquarter: Chiyoda-ku, Tokyo, General Manager: Kennet Brysting, “Gilead”), Eisai Co., Ltd. ....

Bunkyo Ku , United Kingdom , Japan General , Chuo Ku , United States , Chiyoda Ku , Foster City , Great Britain , Norifumi Hibi , Haruo Naito , Mamoru Watanabe , Hidenori Yabune , Kennet Brysting , Eisai Co Ltd , Ea Pharma Co Ltd , Gilead Sciences , European Union , Ministry Of Health , Gilead Sciences Inc , General Manager , Representative Director , Janus Kinase , Advanced Treatment , Inflammatory Bowel Disease , Kitasato Institute Hospital , Tokyo Medical ,